0000899243-20-027297.txt : 20201005
0000899243-20-027297.hdr.sgml : 20201005
20201005170010
ACCESSION NUMBER: 0000899243-20-027297
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200716
FILED AS OF DATE: 20201005
DATE AS OF CHANGE: 20201005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arix Bioscience plc
CENTRAL INDEX KEY: 0001700449
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38707
FILM NUMBER: 201224284
BUSINESS ADDRESS:
STREET 1: 20 BERKELEY SQUARE
CITY: LONDON
STATE: X0
ZIP: W1J 6EQ
BUSINESS PHONE: 44(0)20 7290 1050
MAIL ADDRESS:
STREET 1: 20 BERKELEY SQUARE
CITY: LONDON
STATE: X0
ZIP: W1J 6EQ
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arix Bioscience Holdings Ltd
CENTRAL INDEX KEY: 0001756884
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38707
FILM NUMBER: 201224285
BUSINESS ADDRESS:
STREET 1: 20 BERKELEY SQUARE
CITY: LONDON
STATE: X0
ZIP: W1J6EQ
BUSINESS PHONE: 44(0)20 7290 1050
MAIL ADDRESS:
STREET 1: 20 BERKELEY SQUARE
CITY: LONDON
STATE: X0
ZIP: W1J6EQ
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664106
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471514975
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 HAYDEN AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-245-0399
MAIL ADDRESS:
STREET 1: 65 HAYDEN AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-16
0
0001664106
LogicBio Therapeutics, Inc.
LOGC
0001700449
Arix Bioscience plc
20 BERKELEY SQUARE
MAYFAIR, LONDON
X0
W1J6EQ
UNITED KINGDOM
0
0
1
0
0001756884
Arix Bioscience Holdings Ltd
20 BERKLEY SQUARE
MAYFAIR, LONDON
X0
W1J6EQ
UNITED KINGDOM
0
0
1
0
Common stock
2020-07-16
4
S
0
16332
8.559
D
2962691
I
See footnote
Common stock
2020-07-17
4
S
0
31101
9.24
D
2931590
I
See footnote
Common stock
2020-07-20
4
S
0
36983
9.249
D
2894607
I
See footnote
Common stock
2020-07-22
4
S
0
22651
9.004
D
2871956
I
See footnote
Common stock
2020-07-29
4
S
0
2709
8.781
D
2869247
I
See footnote
Common stock
2020-08-12
4
S
0
1335
8.79
D
2867912
I
See footnote
Common stock
2020-08-13
4
S
0
159
8.75
D
2867753
I
See footnote
Common stock
2020-09-24
4
S
0
38514
7.629
D
2829239
I
See footnote
Common stock
2020-09-25
4
S
0
174219
7.077
D
2655020
I
See footnote
Common stock
2020-09-28
4
S
0
273584
7.5365
D
2381436
I
See footnote
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer.
These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.00 to $8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Arix Bioscience Plc, by: /s/ Marcus Karia, Authorized Officer
2020-10-05
Arix Bioscience Holdings Limited, by: /s/ Marcus Karia, Authorized Officer
2020-10-05